
## Julia Uusna

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/8236631/publications.pdf Version: 2024-02-01



ΙΠΗΥ ΠΗΣΝΑ

#	Article	IF	CITATIONS
1	Implementation of antimicrobial peptides for sample preparation prior to nucleic acid amplification in point-of-care settings. Expert Review of Molecular Diagnostics, 2017, 17, 1117-1125.	3.1	1
2	Optimization of in vivo DNA delivery with NickFect peptide vectors. Journal of Controlled Release, 2016, 241, 135-143.	9.9	56
3	Combination with antimicrobial peptide lyses improves loop-mediated isothermal amplification based method for Chlamydia trachomatis detection directly in urine sample. BMC Infectious Diseases, 2016, 16, 329.	2.9	17
4	Intracellular Target-Specific Accretion of Cell Penetrating Peptides and Bioportides: Ultrastructural and Biological Correlates. Bioconjugate Chemistry, 2016, 27, 121-129.	3.6	14
5	Toxicity, Immunogenicity, Uptake, and Kinetics Methods for CPPs. Methods in Molecular Biology, 2015, 1324, 133-148.	0.9	22
6	Sensitive and Rapid Detection of Chlamydia trachomatis by Recombinase Polymerase Amplification Directly from Urine Samples. Journal of Molecular Diagnostics, 2014, 16, 127-135.	2.8	120
7	PepFect14 Peptide Vector for Efficient Gene Delivery in Cell Cultures. Molecular Pharmaceutics, 2013, 10, 199-210.	4.6	83
8	Peptide-Based Glioma-Targeted Drug Delivery Vector gHoPe2. Bioconjugate Chemistry, 2013, 24, 305-313.	3.6	42
9	Intracellular translocation and differential accumulation of cell-penetrating peptides in bovine spermatozoa: evaluation of efficient delivery vectors that do not compromise human sperm motility. Human Reproduction, 2013, 28, 1874-1889.	0.9	40
10	Cell-Penetrating Peptides, PepFects, Show No Evidence of Toxicity and Immunogenicity <i>In Vitro</i> and <i>In Vivo</i> . Bioconjugate Chemistry, 2011, 22, 2255-2262.	3.6	91
11	Delivery of nucleic acids with a stearylated (RxR)4 peptide using a non-covalent co-incubation strategy. Journal of Controlled Release, 2010, 141, 42-51.	9.9	113
12	Fibrinogen beta variants confer protection against coronary artery disease in a Greek case-control study. BMC Medical Genetics, 2010, 11, 28.	2.1	26
13	ROS1 Asp2213Asn polymorphism is not associated with coronary artery disease in a Greek case-control study. Clinical Chemistry and Laboratory Medicine, 2009, 47, 1471-3.	2.3	6